MarginsXMarginsX
Home › Markets › Health Care › TRDA

Entrada Therapeutics Inc. (TRDA)

TRDA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.00
-1.77% on the day
Market cap
$195.8M
Micro cap
Revenue · 2025
$25.4M
-87.9% on 2024
Net income · 2025
-$143.8M
-565.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1689375/000168937526000011/0001689375-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTRDA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001689375
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$25.4M
Net income-$143.8M
Operating income-$157.9M
Net margin-565.5%
Operating margin-621.1%
Revenue growth-87.9%
Cash$90.4M
Total assets$377.4M
P/E (computed)Net income was not positive
P/S (computed)7.7×

Warning signs

Cash runway
9.9 months
$112.2M cash at September 30, 2026
Share count, 1 year
+2.4%
2025-10-31 to 2026-10-31 · +17.3% over 3 years
Going-concern doubt
Yes
10-Q filed November 5, 2026
Insider net buying, 12 months
-$6.9M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern within 12 months from the date these condensed consolidated financial statements are issued."
10-Q 2026-11-05
Cash and burn$112.2M cash; operating cash flow -$34.1M a quarter.Report 2026-09-30
Shares outstanding39,150,334 (2026-10-31); 38,219,232 a year earlier; 33,368,078 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.6M, sold $8.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$905K-$39.7M-$30.0M$112.2MNo debt tags$4.0M10-Q 2026-11-05
Q2 2026
2026-06-30
$898K-$42.8M-$32.5M$99.3MNo debt tags$4.7M10-Q 2026-08-05
Q1 2026
2026-03-31
$875K-$39.7M-$41.7M$76.4MNo debt tags$5.7M10-Q 2026-05-07
Q4 2025
2025-12-31
$1.3M-$39.2M-$32.2M$90.4MNo debt tags$25.4M10-K 2026-02-26
Q3 2025
2025-09-30
$1.6M-$44.1M-$28.3M$93.3MNo debt tags$61.5M10-Q 2026-11-05
Q2 2025
2025-06-30
$1.9M-$43.1M-$29.5M$72.5MNo debt tags$79.5M10-Q 2026-08-05
Q1 2025
2025-03-31
$20.6M-$17.3M-$38.5M$67.8MNo debt tags$172.2M10-Q 2026-05-07
Q4 2024
2024-12-31
$37.4M$1.1M-$31.6M$101.2MNo debt tags$210.8M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3
S-32025-11-06
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 474 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.1%
1 month+4.7%
3 months-31.7%
Year to date-50.5%
1 year-42.0%
From 52-week high-68.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NGENNervGen Pharma Corp.$1.82-3.19%$195.9M
KROSKeros Therapeutics Inc.$10.03-2.62%$196.8M
GLSIGreenwich LifeSciences Inc.$13.76-7.90%$202.0M
SIGASIGA Technologies Inc.$2.85+4.01%$204.8M
RNACCartesian Therapeutics Inc.$6.08-4.25%$185.5M
CYPHCypherpunk Technologies Inc.$1.93+2.94%$207.4M
NATRNature's Sunshine Products Inc.$10.56+1.93%$183.0M
YARWYarrow Bioscience Inc.$13.93-22.74%$212.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier